Regeneron Pharmaceuticals Inc. News Releases https://investor.regeneron.com/ Regeneron Pharmaceuticals Inc. News Releases en Regeneron and Sanofi Announce Positive Topline Phase 2 Results for IL-33 Antibody in Asthma https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-announce-positive-topline-phase-2-results TARRYTOWN, N.Y. and PARIS , June 21, 2019 /PRNewswire/ --  REGN3500  monotherapy significantly reduced loss of asthma control and improved lung function compared to placebo Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Sanofi today announced that a Phase 2 proof-of-concept trial evaluating Fri, 21 Jun 2019 00:59:00 -0400 Regeneron Pharmaceuticals Inc. News Releases 22546 Regeneron CD20xCD3 Bispecific REGN1979 Shows Positive Results in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, including in CAR-T Failures https://investor.regeneron.com/news-releases/news-release-details/regeneron-cd20xcd3-bispecific-regn1979-shows-positive-results TARRYTOWN, N.Y. , June 14, 2019 /PRNewswire/ -- 93% overall response (13 of 14 patients) and 71% complete response rates (10 of 14 patients) in follicular lymphoma grades 1 to 3a treated with REGN1979 5 mg to 320 mg 57% overall response rate (4 of 7 patients) in diffuse large B-cell lymphoma Fri, 14 Jun 2019 07:00:00 -0400 Regeneron Pharmaceuticals Inc. News Releases 22521 Regeneron Announces Upcoming Investor Conference Presentation https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-investor-conference-presentation-4 TARRYTOWN, N.Y., May 23, 2019 /PRNewswire/ --  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast its presentation at the Goldman Sachs 40 th Annual Global Healthcare Conference at 9:20 a.m. Pacific Time ( 12:20 p.m. Eastern Time ) on Tuesday, June 11, 2019 . Thu, 23 May 2019 09:30:00 -0400 Regeneron Pharmaceuticals Inc. News Releases 22481 Updated Libtayo® (cemiplimab-rwlc) Results Reinforce Durable and Substantial Response Rates in Advanced Cutaneous Squamous Cell Carcinoma https://investor.regeneron.com/news-releases/news-release-details/updated-libtayor-cemiplimab-rwlc-results-reinforce-durable-and TARRYTOWN , N.Y. and CAMBRIDGE, Mass. , May 16, 2019 /PRNewswire/ -- New data at ASCO include more than double the patients previously reported; median overall survival still not reached with a median follow-up of up to 17 months Regeneron Pharmaceuticals, Inc. Thu, 16 May 2019 07:00:00 -0400 Regeneron Pharmaceuticals Inc. News Releases 22136 FDA Approves EYLEA® (aflibercept) Injection for Diabetic Retinopathy https://investor.regeneron.com/news-releases/news-release-details/fda-approves-eylear-aflibercept-injection-diabetic-retinopathy TARRYTOWN, N.Y. , May 13, 2019 /PRNewswire/ -- EYLEA improves diabetic retinopathy and prevents worsening disease that can lead to blindness Diabetic retinopathy is the leading cause of blindness among working-aged American adults Regeneron Pharmaceuticals, Inc. Mon, 13 May 2019 14:45:00 -0400 Regeneron Pharmaceuticals Inc. News Releases 22116 Dupixent® (dupilumab) Approved for Severe Asthma by European Commission https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-approved-severe-asthma-european-commission TARRYTOWN, N.Y. and PARIS , May 7, 2019 /PRNewswire/ -- Only biologic approved in the EU for severe asthma with type 2 inflammation, as characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO) In clinical trials, Dupixent improved lung function and quality of Tue, 07 May 2019 08:59:00 -0400 Regeneron Pharmaceuticals Inc. News Releases 22091 Regeneron Reports First Quarter 2019 Financial and Operating Results https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-first-quarter-2019-financial-and-operating-0 TARRYTOWN, N.Y. , May 7, 2019 /PRNewswire/ --   First quarter 2019 revenues increased 13% to $1.71 billion versus first quarter 2018 First quarter 2019 EYLEA ® (aflibercept) Injection U.S. net sales increased 9% to $1.07 billion versus first quarter 2018 First quarter 2019 EYLEA net sales outside Tue, 07 May 2019 06:30:00 -0400 Regeneron Pharmaceuticals Inc. News Releases 22081 Regeneron Announces Upcoming Investor Conference Presentations https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-upcoming-investor-conference-presentations-4 TARRYTOWN, N.Y. , April 29, 2019 /PRNewswire/ --  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations as follows: Bank of America Merrill Lynch 2019 Healthcare Conference at 8:00 a.m. Pacific Time ( 11:00 a.m. Eastern Time ) on Wednesday, May 15, 2019 Barclays 2019 Mon, 29 Apr 2019 16:01:00 -0400 Regeneron Pharmaceuticals Inc. News Releases 22046 FDA Approves Praluent® (alirocumab) to Prevent Heart Attack, Stroke and Unstable Angina Requiring Hospitalization https://investor.regeneron.com/news-releases/news-release-details/fda-approves-praluentr-alirocumab-prevent-heart-attack-stroke TARRYTOWN, N.Y. and PARIS , April 26, 2019 /PRNewswire/ -- Praluent is the first PCSK9 inhibitor that has shown a meaningful reduction in death from any cause Praluent treatment effect was observed in patients already receiving other lipid-lowering therapies, including maximally-tolerated statins Fri, 26 Apr 2019 19:19:00 -0400 Regeneron Pharmaceuticals Inc. News Releases 22041 CHMP Issues Positive Opinion for Libtayo® (cemiplimab) in Advanced Cutaneous Squamous Cell Carcinoma https://investor.regeneron.com/news-releases/news-release-details/chmp-issues-positive-opinion-libtayor-cemiplimab-advanced TARRYTOWN, N.Y. and PARIS , April 26, 2019 /PRNewswire/ -- - Currently no approved treatments in the European Union for advanced cutaneous squamous cell carcinoma (CSCC) - CSCC is one of the most common skin cancers worldwide Regeneron Pharmaceuticals, Inc. Fri, 26 Apr 2019 11:15:00 -0400 Regeneron Pharmaceuticals Inc. News Releases 22016